GlassScriptPhysician profile
Sarah A Teo
NPI 1487204665
$10,837.61
in general payments reported to CMS, 2019-2025
31 companies · $3,178 in 2025
The $3,178 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $186 · 2022: $783 · 2023: $3,107 · 2024: $3,584 · 2025: $3,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,231 · Education: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,230.98 |
| Education | $638.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,181.92 | 2022-2025 | |
| Abbvie INC. | $1,140.93 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $938.28 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $876.28 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $875.12 | 2023-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $823.22 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $647.54 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $485.04 | 2023-2025 | Zoryve |
| Ucb, INC. | $474.79 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $473.75 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $462.34 | 2023-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $381.71 | 2022-2025 | Aklief, Oracea, Nemluvio |
| Amgen INC. | $378.42 | 2022-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $355.67 | 2023-2025 | |
| Pfizer INC. | $211.32 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $199.29 | 2022-2025 | Cabtreo, Arazlo, Jublia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.65 | 2023-2024 | Spevigo |
| Kyowa Kirin, INC. | $145.72 | 2021 | |
| Genzyme Corporation | $137.51 | 2024-2025 | |
| Leo Pharma INC. | $121.22 | 2024-2025 | Anzupgo, Spevigo, Adbry |
| Organon LLC | $70.61 | 2025 | Vtama |
| Springworks Therapeutics, INC. | $57.70 | 2025 | Gomekli |
| Lnhc, INC | $39.61 | 2025 | Zelsuvmi |
| Helsinn Therapeutics (U.S.), INC. | $36.25 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $33.60 | 2024-2025 | Ycanth |
| Journey Medical Corporation | $20.76 | 2022 | |
| Almirall LLC | $20.67 | 2024 | Klisyri |
| Bausch Health US, LLC | $19.93 | 2021 | |
| Biocon Biologics INC | $18.11 | 2024 | Hulio |
| Epi Health, LLC | $16.61 | 2022 | |
| Organogenesis INC. | $16.04 | 2024 | Affinity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Teo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.